Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma U.S. FDA accepted Bristol Myers Squibb and 2seventy…
Novo Nordisk raises sales and operating profit outlook for 2023 Novo Nordisk today announced the sales and operating profit growth at constant exchange rates (CER) for the first three months…
Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity Aspect Biosystems and Novo Nordisk A/S today announced a collaboration, development, and licence agreement…
Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the European Commission (EC) granted marketing…
FDA approves Roche’s Policy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the…
Roche’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study Roche (SIX: RO, ROG; OTCQX: RHHBY)…
Roche data highlights the strength of the ophthalmology portfolio and commitment to advancing eye care at ARVO 2023 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data for…
AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST) Amgen (NASDAQ:AMGN) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the District of…
Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities Eli Lilly and Company (NYSE: LLY) announced today that it will invest an additional $1.6 billion and add another 200 new jobs at its…
U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the…
Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement PRNewswire/ — Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023. Lilly will also…
Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023 TEL AVIV, Israel–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd. (NYSE and…